Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor‑mutated 
non‑small cell lung cancer: A case report

Zhao,Qiong; Wang,Yina; Tang,Yemin; Peng,Ling

doi:10.3892/ol.2013.1657

Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor‑mutated non‑small cell lung cancer: A case report

Authors:
- Qiong Zhao
- Yina Wang
- Yemin Tang
- Ling Peng
View Affiliations

Affiliations: Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: November 5, 2013 https://doi.org/10.3892/ol.2013.1657
Pages: 171-176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As kidney transplant recipients are at increased risk of developing cancer, regular monitoring should be undertaken to monitor the balance between immunosuppression and graft function and to identify malignancy. The present study reports the outcome of the treatment of adenocarcinoma of the lung (T1aN0M1a, stage IV) using the molecular‑targeted therapy, icotinib, in a 66‑year‑old male renal transplant patient receiving rapamycin and prednisolone as ongoing renal immunosuppressive therapy. An initial partial response to icotinib was achieved, and graft function remained good. However, the patient subsequently developed interstitial pneumonitis. The plasma concentrations of rapamycin and icotinib were within the normal ranges, which excluded the possibility of a pharmacokinetic drug interaction and indicated that the interstitial pneumonitis was likely to be associated with the side‑effects of icotinib. Drug therapy was discontinued and the patient underwent a segmentectomy. Tacrolimus was administered for ongoing renal graft immunosuppression. To the best of our knowledge, this is the first report of the concomitant administration of icotinib and rapamycin in post‑transplant de novo lung cancer. It is also the first report of interstitial pneumonitis associated with icotinib in a post‑transplant patient.

View Figures

View References

1	Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 306:1891–1901. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kasiske BL, Snyder JJ, Gilbertson DT and Wang C: Cancer after kidney transplantation in the United States. Am J Transplant. 4:905–913. 2004. View Article : Google Scholar : PubMed/NCBI
3	Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest. 136:260–271. 2009. View Article : Google Scholar
4	Zhao Q, Shentu J, Xu N, et al: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 73:195–202. 2011. View Article : Google Scholar : PubMed/NCBI
5	Taylor L, Hughes RA and McPherson K: The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol. 11:1412004. View Article : Google Scholar : PubMed/NCBI
6	Kauffman HM, Cherikh WS, McBride MA, Cheng Y and Hanto DW: Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int. 19:607–620. 2006. View Article : Google Scholar : PubMed/NCBI
7	Webster AC, Lee VW, Chapman JR and Craig JC: Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 81:1234–1248. 2006. View Article : Google Scholar
8	Campistol JM, Eris J, Oberbauer R, et al: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 17:581–589. 2006. View Article : Google Scholar
9	Kahan BD, Yakupoglu YK, Schoenberg L, et al: Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 80:749–758. 2005. View Article : Google Scholar
10	Kauffman HM, Cherikh WS, Cheng Y, Hanto DW and Kahan BD: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 80:883–889. 2005. View Article : Google Scholar
11	Barber NA and Ganti AK: Pulmonary toxicities from targeted therapies: a review. Target Oncol. 6:235–243. 2011. View Article : Google Scholar : PubMed/NCBI
12	Singer SJ, Tiernan R and Sullivan EJ: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 343:1815–1816. 2000. View Article : Google Scholar : PubMed/NCBI
13	Pham PT, Pham PC, Danovitch GM, et al: Sirolimus-associated pulmonary toxicity. Transplantation. 77:1215–1220. 2004. View Article : Google Scholar : PubMed/NCBI
14	Morelon E, Stern M, Israel-Biet D, et al: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 72:787–790. 2001. View Article : Google Scholar : PubMed/NCBI
15	Herbst RS, Prager D, Hermann R, et al: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005. View Article : Google Scholar
16	Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
17	Gemma A: Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med Sch. 76:4–8. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hotta K, Kiura K, Takigawa N, et al: Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar
19	Cohen MH, Williams GA, Sridhara R, et al: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 10:1212–1218. 2004. View Article : Google Scholar : PubMed/NCBI
20	Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 24:2549–2556. 2006. View Article : Google Scholar : PubMed/NCBI
21	Hotta K, Kiura K, Tabata M, et al: Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J. 11:417–424. 2005. View Article : Google Scholar
22	Takano T, Ohe Y, Kusumoto M, et al: Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 45:93–104. 2004. View Article : Google Scholar : PubMed/NCBI
23	Danson S, Blackhall F, Hulse P and Ranson M: Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 28:103–113. 2005. View Article : Google Scholar : PubMed/NCBI
24	Suzuki M, Asahina H, Konishi J, Yamazaki K and Nishimura M: Recurrent gefitinib-induced interstitial lung disease. Intern Med. 47:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
25	Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 5:2676–2684. 2006. View Article : Google Scholar
26	Costa LJ, Gemmill RM and Drabkin HA: Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology. 69:596–602. 2007. View Article : Google Scholar : PubMed/NCBI
27	Reardon DA, Desjardins A, Vredenburgh JJ, et al: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 96:219–230. 2010. View Article : Google Scholar : PubMed/NCBI
28	Flaig TW, Costa LJ, Gustafson DL, et al: Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer. 103:796–801. 2010. View Article : Google Scholar
29	Kris MG, Riely GJ, Azzoli CG, et al: Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial. J Clin Oncol. 25(Suppl 18): 403S2007.
30	Weir MR, Diekmann F, Flechner SM, et al: mTOR inhibition: the learning curve in kidney transplantation. Transpl Int. 23:447–460. 2010. View Article : Google Scholar : PubMed/NCBI
31	Ajithkumar TV, Parkinson CA, Butler A and Hatcher HM: Management of solid tumours in organ-transplant recipients. Lancet Oncol. 8:921–932. 2007. View Article : Google Scholar : PubMed/NCBI
32	Tan F, Shen X, Wang D, et al: Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 76:177–182. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zhang GC, Lin JY, Wang Z, et al: Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol). 19:499–506. 2007. View Article : Google Scholar
34	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI